Lifileucel plus Pembrolizumab + Pembrolizumab with Optional Crossover Period
Phase 3RecruitingInterest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Trial Timeline
Mar 30, 2023 → Mar 1, 2030
NCT ID
NCT05727904About Lifileucel plus Pembrolizumab + Pembrolizumab with Optional Crossover Period
Lifileucel plus Pembrolizumab + Pembrolizumab with Optional Crossover Period is a phase 3 stage product being developed by Iovance Biotherapeutics for Metastatic Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05727904. Target conditions include Metastatic Melanoma, Unresectable Melanoma, Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05727904 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Melanoma